Last reviewed · How we verify

NCT02879760

Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients

Completed Phase 1, PHASE2 Last updated 6 October 2020
What this trial tests

Phase 1, PHASE2 trial testing Ad-MAGEA3 in Non-Small Cell Lung Cancer in 16 participants. Completed in 24 May 2020.

Timeline
8 March 2017
Primary endpoint
15 February 2020
24 May 2020

Quick facts

Lead sponsorTurnstone Biologics, Corp.
PhasePhase 1, PHASE2
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment16
Start date8 March 2017
Primary completion15 February 2020
Estimated completion24 May 2020
Sites6 locations across Canada

Drugs / interventions tested

Conditions studied

Sponsor

Turnstone Biologics, Corp. — full company profile →

Who can join

18 and older, any sex, with Non-Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1/2, multi-center, open-label, dose-escalation trial of Ad-MAGEA3 and MG1-MAGEA3 in combination with pembrolizumab in patients with Non-Small Cell Lung Cancer who have completed a first standard therapy with at least 1 cycle of platinum based chemotherapy and/or at least one treatment of PD-1 or PD-L1 antibody targeted therapy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Viral vector platforms within the gene therapy landscape.
    Bulcha JT, Wang Y, Ma H, Tai PWL, et al · · 2021 · cited 899× · PMID 33558455 · DOI 10.1038/s41392-021-00487-6
  2. Lung cancer immunotherapy: progress, pitfalls, and promises.
    Lahiri A, Maji A, Potdar PD, Singh N, et al · · 2023 · cited 737× · PMID 36810079 · DOI 10.1186/s12943-023-01740-y
  3. Type I interferon-mediated tumor immunity and its role in immunotherapy.
    Yu R, Zhu B, Chen D. · · 2022 · cited 229× · PMID 35292881 · DOI 10.1007/s00018-022-04219-z
  4. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy.
    Tian Y, Xie D, Yang L. · · 2022 · cited 199× · PMID 35387984 · DOI 10.1038/s41392-022-00951-x
  5. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
    Genova C, Dellepiane C, Carrega P, Sommariva S, et al · · 2021 · cited 168× · PMID 35069581 · DOI 10.3389/fimmu.2021.799455
  6. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
    Shi T, Song X, Wang Y, Liu F, et al · · 2020 · cited 134× · PMID 32411132 · DOI 10.3389/fimmu.2020.00683
  7. Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds.
    Sivanandam V, LaRocca CJ, Chen NG, Fong Y, et al · · 2019 · cited 124× · PMID 31080879 · DOI 10.1016/j.omto.2019.04.003
  8. Oncolytic Viruses-Natural and Genetically Engineered Cancer Immunotherapies.
    Jhawar SR, Thandoni A, Bommareddy PK, Hassan S, et al · · 2017 · cited 123× · PMID 28955655 · DOI 10.3389/fonc.2017.00202

Verify or expand the search:

Other trials of Ad-MAGEA3

Trials testing the same drug.

Other recruiting trials for Non-Small Cell Lung Cancer

Currently open trials in the same condition.

Other Turnstone Biologics, Corp. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02879760.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing